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Abstract
Background: Epithelial mesenchymal transition (EMT) is a crucial event likely involved in dissemination of epithelial
cancer cells. This process enables them to acquire migratory/invasive properties, contributing to tumor and
metastatic spread. To know if this event is an early one in breast cancer, we developed a clinical trial. The aim of
this protocol was to detect circulating tumor cells endowed with mesenchymal and/or stemness characteristics, at
the time of initial diagnosis. Breast cancer patients (n = 61), without visceral or bone metastasis were enrolled and
analysis of these dedifferentiated circulating tumor cells (ddCTC) was realized.
Methods: AdnaGen method was used for enrichment cell selection. Then, ddCTC were characterized by RT-PCR
study of the following genes: PI3Ka, Akt-2, Twist1 (EMT markers) and ALDH1, Bmi1 and CD44 (stemness indicators).
Results: Among the studied primary breast cancer cohort, presence of ddCTC was detected in 39% of cases. This
positivity is independant from tumor clinicopathological factors apart from the lymph node status.
Conclusions: Our data uniquely demonstrated that in vivo EMT occurs in the primary tumors and is associated
with an enhanced ability of tumor cells to intravasate in the early phase of cancer disease. These results suggest
that analysis of circulating tumor cells focused on cells showing mesenchymal or stemness characteristics might
facilitate assessment of new drugs in clinical trials.
Background
Many trials are currently focusing on circulating tumor
cells (CTC) in peripheral blood and publications have
described association of CTC with worse prognosis [1].
The term CTC encompasses all types of cells which are
considered as foreign entities in the blood having some
cancerous characters. Often, in this whole population,
cells with tumorigenic potential are not detected. Results
are essentially supported by cell counting data arising
from CellSearch (Veridex, Raritan, NJ). This method has
been cleared by FDA but is not endorsed, like others, by
ASCO recommendations. Recent studies have suggested
that CellSearch technique may underestimate the num-
ber of CTC [2]. Blood intravasation of cancer cells from a
primary breast carcinoma is an early event, leading to
metastasis [3,4]. Klein et al proposed a parallel progres-
sion between early primary tumor and dissemination of
tumor cells [5]. Evidence has emerged that CTC present
a heterogeneity as the one described for primary tumors.
Subpopulations of CTC: cancer stem cells, tumor ampli-
fying cells (i.e progenitors) and tumor initiating cells
arise from epithelial cancer cells of the primary tumor
undergoing epithelial mesenchymal transition (EMT)
program [6,7]. Targeting these types of cells, cancer stem
cells [8] and mesenchymal cells in the blood, would pro-
vide more clinically relevant prognosis and predictive
information than simple CTC counting. Their analysis
should help in a more tight follow-up of the disease
progression.
For epithelial malignancies, EMT is a crucial event in
the dissemination of cancer cells. Carcinoma epithelial
cells are linked to their neighbours and to basal mem-
branes by protein junctions which are abolished when
cells acquire a migratory mesenchymal phenotype. The
EMT process is regulated by pleiotropic cytokines such
as TGFb acting through the “cadherin switch” [9]. Cell
adhesion proteins are transcriptionally repressed by clas-
sical EMT-related signaling pathways. Among them,
PI3Ka/Akt-2/mTOR network acts to modulate cell survi-
val, migration and resistance to anoikis and apoptosis
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breast cancer cells leading to increase migration and
invasion [12]. EMT is associated with acquisition of stem
cell-like characteristics: Bmi1, a protein that promotes
and maintains self-renewal, is a direct transcriptional tar-
get of the EMT inducer Twist1 [13]. Studies indicated
that ALDH1, responsible for oxidation of retinol to reti-
noic acid, is a potent marker of breast cancer stem cells
[14]. In breast cancer, CD44
+/CD24
-/low cells are known
to be highly tumorigenic in immunodeficient mice [15].
These markers are useful for identification of CTC hav-
ing EMT and/or stemness phenotypes. We named dedif-
ferentiated circulating tumor cells (ddCTC) only the
subpopulations having one or several mesenchymal and/
or stemness characteristics. Due to these considerations,
we started a preliminary study for detection of ddCTC at
the time of the early breast cancer diagnosis. These ana-
lyses were performed before any therapy. EMT and stem-
ness marker expressions were analyzed in order to
identify ddCTC.
Methods
Patient population
The study was conducted at the department of gynecologi-
cal surgery (Private Hospital Clinique le Colombier) and
Astralab laboratory (Department of specialized medical
analyses) in Limoges Fr. Since January 2011, patients have
been included and blood samples collected before any
therapy. Among them, 61 patients were selected provided
they showed the following criteria: age 40-75 years, breast
cancer diagnosis confirmed by pathologist analysis of the
primary tumor, absence of bone, visceral, cerebral metas-
tasis (controlateral breast mammography, liver ultrasono-
graphy and entire body bone scanning). Axillary lymph
node invasion was assessed.
This protocol was performed with the approval of the
appropriate ethic local committee (Comité de protection
des personnes Sud-Ouest et Outre-mer IV. France) and
was in compliance with the Helsinki Declaration.
Sampling of biological material
Blood samples of 7 ml were collected for cellular enrich-
ment with AdnaCollect tubes (AdnaGen AG, Langenha-
gen, Germany) and were stored and shipped in the dark at
4-8°C. Samples were analysed within 24 hours. Blood col-
lection tubes contain EDTA and an agent preventing ille-
gitimate RNA expression. Selection and detection steps of
CTC were led as published [16,17]. They are briefly
summarized.
Selection of CTC
Tumor cells enrichment was realized by using immuno-
magnetic beads coated with three antibodies, one against
EpCam, two others against Muc-1. One of the latter
directed to an underglycosylated epitope, stably not
accessible in other blood cells, is more specific of cancer
cells. During this enrichment step of mesenchymal and
stem breast cancer cells a special washing buffer proce-
dure allowed to avoid excess of contaminating leucocytes.
AdnaGen kits were used following supplier recommenda-
tions (AdnaTest EMT-1/Stem CellSelect, AdnaGen AG,
Langenhagen, Germany).
Detection
Then, AdnaTest EMT-1/Stem CellDetect kit was used,
according to supplier information (AdnaGen AG, Lan-
genhagen Germany). The analysis of tumor-associated
mRNA, isolated from tumor cells, was performed by
RT-PCR for the following transcripts: PI3Ka,T w i s t 1 ,
Akt-2 and ALDH1. Thermal profiles used are those
recommended by the supplier.
We added CD44 and Bmi1 as subsidiary markers of
stemness. For each one, RT sample previously obtained
was amplified by singleplex PCR. Sequences of primers
are: CD44 forward GCCCAATGCCTTTGATGGACC,
CD44 reverse GCAGGGATTCTGTCTGTGCTG and
Bmi1 forward CATTGTCTTTTCCGCCCGC, Bmi1
reverseCAAAGCACACACATCAGGTGGG. The thermal
profile used for CD44 PCR was as follows: after15 min
denaturation at 95°C, 33 cycles of PCR were carried out by
denaturation at 94°C for 30 s, annealing/extension at 59°C
for 30 s, and elongation for 72°C for 30 s. Termination of
the PCR reaction was subsequently carried out at 72°C for
5 min followed by storage of the sample at 10°C. The one
for Bmi1 was as follows: after 15 min denaturation at 95°
C, 36 cycles of PCR were carried out by denaturation at
94°C for 30 s, annealing/extension at 59.7°C for 30 s, and
elongation for 72°C for 30 s. Termination of the PCR reac-
tion was subsequently carried out at 72°C for 5 min fol-
l o w e db ys t o r a g eo ft h es a m p l ea t1 0 ° C .T h ep r i m e r s
generate fragments of the following sizes (257 bp CD44
-132 bp Bmi1).
Sensiscript and HotStarTaq from Qiagen GmbH (Hil-
den, Germany) were used for RT and amplication of
cDNA templates.
Electrophoretic analysis of PCR fragments
Visualization of PCR fragments was carried out with 2100
bioanalyser (Dna1000 LabChip Agilent technologies).
Peaks were considered as positive when concentration was
≥0.15 ng/μL (according to AdnaGen indications). CD44
and Bmi1 expressions were considered positive when tran-
script concentration was above 0.50 ng/μl. Blood collected
from 20 healthy donors was investigated to determine this
cut-off value. To confirm it, larger investigation will be
implemented.
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Statistical analysis were performed using Software
XLStat2011. Khi2 test was used to establish a relation-
ship between ddCTC detection and tumor characteris-
tics or lymphatic invasion. As the size of the sample was
small we controled Khi2 test results by using the Barnet
Woolf [18] and Adjusted R Squared tests.
Results
Patient characteristics
All patients (aged from 40 to 75 years, average 66 years)
were studied at the time of newly diagnosed breast cancer
and have been included after elimination of bone visceral
and cerebral metastasis, whether they had or not an axil-
lary lymphatic node invasion. Analyses were performed
before any therapy. Table 1 describes clinical and patholo-
gists’ characteristics of the tumor. This table indicated the
major features of each tumor and their molecular charac-
teristics as proposed in numerous publications [19,20]. We
distinguished four tumor types: luminal A (53 cases), lumi-
nal B (3 cases), overexpressed Her-2 (1 case) and triple
negative carcinoma (4 cases). Values (mean ± SD) of Ki67
index were respectively for these tumor types: 11(± 7), 27
(± 3), 30, and 13 (± 3). Infiltrant lobular or infiltrant ductal
carcinoma were indicated. Most of the patients had no
positive axillary lymph nodes (45 upon 61); Four primary
tumors expressed Her-2 (Dako, score 3 plus/Fish). Estro-
gen receptors (ER) were expressed in 95% of examined
tumors.
EMT-Stemness detection
Among 61 patients, 24 had ddCTC expressing at least
one EMT or ALDH1 markers. Thus 39% of the total
cohort were positive for ddCTC (Table 2). Moreover
among this population 31%, 21% and 13% showed
respectively EMT cell, stem cell, both EMT and stem cell
markers (Figure 1a). Rate analysis of markers for 24 posi-
tive patients is delineated in Figure 1b (Twist1 13%,
PI3Ka 67%, Akt-2 13%, and ALDH1 54%). When ana-
lyses detected at least one EMT marker or ALDH1, the
sample was further examined for Bmi1 and CD44. For
these 2 markers, we applied a transcript cut-off value of
0.50 ng/μL (specificity of the cut-off is more than 90%, as
confirmed in 20 healthy donor samples). Thus, ddCTC
detected by mesenchymal and/or ALDHI markers, were
67% and 33% positive for Bmi1 and CD44 respectively.
Among 45 N
- patients, 21 showed ddCTC and upon 16
N
+ patients only 3 had ddCTC.
Statistical results
Statistical studies indicated that ddCTC detection is an
independant factor of the primary tumor characteristics
but not of the lymph node status (Table 2). Results of Khi
2 test were corroborated by an other reliable test: Barnet
Woolf. There was a relationship between ddCTC positivity
and the absence of lymph node invasion p = 0.050, (risk =
5%) and values of Adjusted R
2 had a significance level for
= 0.05. Presence of ddCTC was predominant when
patients were lymph node negative: 47% of N
- patients and
19% of N
+ patients were ddCTC positive. This correlation
between lymphatic invasion and ddCTC was not pre-
viously demonstrated for patients at baseline primary
breast cancer diagnosis. However we must keep in mind
that lymphatic internal mammary chain has not been
explored.
Discussion
It seemed us important to develop analyses able to detect
cells which are arising from EMT and spreading into the
blood stream. Many arguments reported in recent litera-
ture sustained the choice of markers used in our study:
PI3Ka, Akt-2, Twist1, ALDH1, Bmi1, CD44 [14-16]. In
breast cancer, some patients develop metastasis many
years after the apparently successful therapy of the pri-
mary cancer. The residual cancer disease is based on the
notion of occult metastatic tumor cells in bone marrow.
Metastasis formation from epithelial tumors progresses
through dissemination of tumor cells that can follow two
major ways: bloodstream or lymphatic vessels [6]. Cancer
cell invasion seems proceed from EMT program [21].
Table 1 Primary tumour and lymph node status of the
total cohort
Patient cohort characteristics Cohort
Number 61
Histology Invasive ductal carcinoma 47
Invasive lobular carcinoma 11
Others 3
Molecular Luminal A 53
Characteristics Luminal B 3
Triple negative 4
Her2 overexpression 1
Size tumour T1 29
T2 28
T3 and T4 4
Lymph node status N+ 16
N- 45
Tumor grade I1 3
II 36
III 9
Unknown 3
Hormonal ER+ 58
status PR+ 46
Her-2 status Her2 + 4
Her2 - 57
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ways that confer new characteristics to the cells: apopto-
sis resistance, chemo and radio resistance. EMT can be
viewed as a continuum of a progressive dedifferentiation
leading to cells with stem-cell like properties. Overex-
pression of a few EMT regulators may be sufficient to
generate the cancer stem cell phenotype [22]. A molecu-
lar link between EMT and stemness emerged with the
finding that Bmi1 is a direct transcriptional target of the
EMT inducer Twist1 [23]. These phenomena establish a
hierarchy of cancer cell phenotypes from mesenchymal
to stemness status.
Our results led to classify patients as follows. The first
phenotype of ddCTC is essentially mesenchymal with
markers of EMT. Among the 3 markers, the predominant
one is PI3Ka,t h e ni ne q u a lp r o p o r t i o n sA k t - 2a n d
Twist1. The second phenotype is characterized by
ALDH1 expression, a stemness marker. The third pheno-
type is a mixture of the two previous ones and represents
33% of positive patients.
Aktas et al evaluated 226 blood samples of 39 meta-
static breast cancer patients during a follow-up of differ-
ent therapies for the expression of the stem cell and
EMT markers [16]. In 31% of detected CTC positive sam-
ples, 62% were positive for at least one of the EMT mar-
kers and 69% for ALDH1. Thus they demonstrated for
the first time that a major proportion of CTC of meta-
static breast cancer patients shows EMT and tumor stem
cell characteristics. In another study, Kallergi et al identi-
fied in patients with early and metastatic breast cancer,
Table 2 Results of ddCTC detection and statistical analysis
Khi2 Barnet Woolf
Patient cohort characteristics negative
ddCTC
positive
ddCTC
PP
Number 37 24
NS NS
Histology Invasive ductal carcinoma 28 19
Invasive lobular carcinoma 83
Others 12
NS NS
Molecular Luminal A 32 21
Characteristics Luminal B 21
Triple negative 22
Her2 overexpression 10
NS NS
Size tumour T1 17 12
T2 18 10
T3 and T4 22
0.05* < 0.05*
Lymph node N+ 13 3
status
N- 24 21
NS NS
Tumor grade I 85
II 22 14
III 54
Unknown 21
ND ND
Hormonal ER+ 37 21
status ER- 03
NS NS
PR+ 28 18
PR- 96
Values of P for Khi2 and Barnet Woolf tests are indicated for each clinicopathological characteristics of tumors
*significance level: P 0.05, NS: P > 0.05 for alpha risk 5%; ND: not determined
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these cells in metastasis disease than in early stage breast
cancer supports the hypothesis that EMT is involved in
metastatic potential of CTC [24]. Moreover the detection
rates they reported are similar to ours. In our study, 39%
of patients who were positive for EMT and ALDH1 mar-
kers had Bmi1 and CD44 positive cells in 67% and 33%
respectively. The expression of Bmi1 and CD44 arose in
26% and 13% of ddCTC samples. These results support
the stemness characters of these positive samples. Indeed
it was shown that EMT generates cells with stem like
properties [25,26] and that the stemness factor Bmi1 is
regulated by Twist1 [23].
It is the first time that ddCTC presence in the blood is
demonstrated with such a high rate (24/61 patients) at
least when the primary breast tumor is diagnosed without
metastasis. If CTC are considered as a prognostic factor,
our results showed clearly that detection of all cell phe-
notypes should be taken into account to have an idea of
the disease progression. Ongoing trials in our laboratory
indicate that ddCTC are more frequently detected than
CTC characterized by AdnaTestBreastCancerSelect and
Detect kits (GA733-2, Muc-1 and Her-2) in primary
breast cancer patients. Preliminary results, upon 400
patients showed that 8% of patients are positive for CTC
according to this previous basic AdnaGen kit (data not
shown). This result is not so far from those of the litera-
ture. Banys et al. found 12% of positive patients upon
a b o u t2 0 9 ,b yu s i n gt h es a m ea n a l y t i c a lt e s t[ 1 7 ] .B r a u n
et al demonstrated that incidence of bone marrow micro-
metastasis (disseminated tumor cells) was similar in
patients with lymph node metastasis and those whithout
[27]. Moreover Menard et al suggested that lymph node
metastasis are not necessarily associated with cancer
hematogenous spread [28]. Our results stress that
absence of lymph node invasion is not a criteria of non
dissemination. Among 45 N
- patients 47% showed a
ddCTC positive profile and upon 16 N
+ patients only
19% had a positive profile. Nevertheless such a result
does not weaken the negative pronostic value of lymph
node invasion. These results could be explained as indi-
cated by Chaffer and Weinberg that spread to other sites
occurs mostly via the blood stream [6]. Our results are in
agreement with their observations. Albeit statistical
results indicated a relationship between axillary node
invasion and detection of ddCTC, the significance level
had a borderline value (p = 0.05). These preliminary sta-
tistical results have to be confirmed by a larger trial
avoiding an inaccurate inference of Khi2.
Some methods for CTC analyses detect entities that
by all criteria are cancer cells but which lack the ability
to invade, proliferate and cause metastasis [29]. We can
speculate according to these previous publications, that
the CTC population is an heterogeneous one. According
to these observations, our results showed dedifferen-
tiated EMT and stemness subpopulations in primary
breast cancer patients. Such a discrimination had been
suggested by Mego et al. [30]. Indeed they demonstrated
that metastatic breast cancer patients, had substantially
different prognosis correlated to CTC subpopulations. A
future prospective study is warranted to determine the
incidence of ddCTC characterization on the prognosis.
We believe that follow-up of ddCTC may facilitate the
monitoring of therapeutic agents targeting these cells.
Conclusions
Most CTC studies have been conducted in metastatic
breast cancer to establish the prognostic value of this
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Figure 1 Detection of circulating mesenchymal and cancer stem cells in early breast cancer. a) Rates of ddCTC and cell subpopulations
among the total cohort. b) Rates of EMT and stemness markers for 24 positive patients.
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primary breast cancer. In a cohort of patients without
metastasis, our results showed that ddCTC with EMT
and stemness characteristics can be detected. Although
they are tumor initiating cells, majority of them are
often not detected by generally used technologies in
clinical trials. The demonstration of EMT program acti-
vation, leading to invasive properties and stemness of
cancer cells, seems to be a new way to characterize
CTC. The relationship between ddCTC and lymph node
invasion suggests that blood is a major dissemination
route. The disease status should be analyzed by the
quantitative measurement of EMT gene expression. It
could be efficient to control new drugs targeting
mesenchymal cells. Eradication of ddCTC would be the
proof of therapeutic effectiveness in clinical trials.
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